Folotyn for Non-Hodgkin's Lymphoma Lockport NY

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Local Companies

Nikolaos Botsoglou
(716) 896-5922
2475 Harlem Rd
Cheektowaga, NY
SULEYMAN SARPEL, MD
(716) 298-1263
6934 Williams Road
Niagara Falls, NY
ROBERT MOSKOWITZ, MD
(716) 630-1066
295 Essjay Road
Buffalo, NY
Helen Hess Cappuccino, MD
716-438-9486
5700 Leete Rd
Lockport, NY
Dr.Amy Early
(716) 630-1029
295 Essjay Road
Buffalo, NY
Merav Sendowski
(716) 862-3191
3495 Bailey Ave
Buffalo, NY
Jeon H Lee
(716) 634-6503
626 Frankhauser Rd
Williamsville, NY
MARY PETRUZZI, MD
(716) 878-7349
219 Bryant Street
Buffalo, NY
M Steven Piver, MD
716-862-1310
2157 Main St
Buffalo, NY
Malabika De, MD
2605 Harlem Rd
Cheektowaga, NY
Data Provided by:
      

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Green Tea and Hematologic Malignancies Lockport NY
Read more about Green Tea May Lower the Risk of Hematologic Malignancies.
- Donor Stem-Cell Transplant for Acute Myeloid Leukemia Lockport NY